Recently, the "2026 China Top 100 Pharmaceutical Innovation Enterprises" list was officially announced, with Xuanzhu Biotech successfully making the list thanks to its solid strategic layout and outstanding achievements in innovative drug research and development.

This ranking was developed by E-Drug Manager in collaboration with Clarivate's Cortellis Drug Development Data Platform. It evaluates domestic pharmaceutical companies' comprehensive innovation capabilities across three dimensions—innovation foundation, innovation process, and innovation outcomes—by integrating four key quantitative indicators: patents, clinical trials, new drug approvals, and market launches, providing an objective assessment of their overall R&D strength.

For a long time, Xuanzhu Biotech has adhered to independent innovation, focusing on major disease areas such as digestive disorders, oncology, and non-alcoholic fatty liver disease. The company has continuously advanced the development and implementation of multiple small-molecule and biopharmaceutical pipelines, aiming to address unmet clinical needs with high-quality innovative drugs. This recognition represents high industry acclaim for the company's robust R&D capabilities and potential for industrialization.

In the future, Xuanzhu Biotech will continue to increase its R&D investment, strengthen its innovation research platform, and accelerate the market launch of high-quality innovative drugs, contributing to the high-quality development of China's pharmaceutical industry.

About Xuanzhu Biopharm:

Xuanzhu Biopharm (Stock Code: 02575.HK) is an innovative pharmaceutical company rooted in China with a global vision, focusing on major disease areas such as digestive disorders, oncology, and non-alcoholic fatty liver disease. The company is dedicated to the research, development, production, and commercialization of Class 1 new drugs based on core proprietary technologies. It boasts a top-tier R&D team, with key members possessing extensive experience in new drug development. As a cutting-edge player in commercially viable innovative drugs driven by R&D and AI empowerment, the company has established a unique product pipeline that encompasses small-molecule chemical drugs, large-molecule biologics, antibody-drug conjugates, and more—a rarity in China. Guided by unmet clinical needs, the company strives to become a leading innovative pharmaceutical enterprise with comprehensive capabilities in independent R&D, production, and sales.